Studies suggest that tomato and soy foods may contribute to a lower risk of 
certain cancers. We developed a novel soy germ tomato juice to be used in 
controlled cancer prevention trials. This study describes an initial test of 
compliance, phytochemical bioavailability, and effects on biomarkers of blood 
lipids. Healthy men and women (n = 18) consumed a soy germ-fortified juice daily 
(300 mL supplying 66 mg isoflavones and 22 mg lycopene) for 8 wk. A single-dose 
bioavailability study was completed on day 1 and isoflavones in plasma and 
urine, and lycopene in the plasma, were measured. All subjects completed the 
trial, with 97.7% ± 3.5% (mean ± SD) of the scheduled juice consumed. No adverse 
effects were documented. The postprandial study indicated that 3.1% ± 2.3% of 
lycopene was absorbed and that 49.3% ± 12.1% isoflavones ingested were recovered 
in 24-h urines. Lycopene plasma concentration changed from 0.60 ± 0.22 to 1.24 ± 
0.30 μmol/L during 8 wk of consumption. Juice consumption significantly improved 
resistance of LDL+VLDL-C to Cu(2+)-mediated oxidation (P = 0.039), HDL-C (47.3 ± 
15.8 to 51.7 ± 14.8 mg/dL, P < 0.001), and the ratio of total-C/HDL-C (4.25 ± 
1.59 to 3.63 ± 1.16, P < 0.001) at 8 wk. A well-characterized soy-fortified 
tomato juice can be produced in large scale for multiinstitutional long-term 
cancer prevention trials and showed excellent compliance with no toxicity, while 
demonstrating absorption of biologically active phytochemicals.